Pluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 Million
May 05, 2020 09:56 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Recaps Investor & Analyst Call Reviewing European Investment Bank’s €50 Million Financing
April 30, 2020 09:30 ET
|
Pluristem Therapeutics, Inc.
• Elaborating on agreement terms and tranches schedule• Provides update on cash position and clinical program HAIFA, Israel, April 30, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc....
EIB signs collaboration with Israel Innovation Authority and €50 million financing agreement with Pluristem to develop therapies for COVID-19 and other unmet medical needs
April 30, 2020 02:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, April 30, 2020 (GLOBE NEWSWIRE) -- European Investment Bank (EIB) backs Pluristem with €50 million of financing, which will help the company to advance the clinical...
The European Investment Bank (EIB), EU Delegation to Israel, the Israel Innovation Authority, and Pluristem Cordially Invite the Public to an Online Signing Ceremony on April 30, 2020
April 27, 2020 06:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, April 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Secures €50 Million Non-Dilutive Financing from the European Investment Bank to Support its COVID-19 Project and Phase III Studies
April 24, 2020 06:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, April 24, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Expands its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program
April 13, 2020 06:00 ET
|
Pluristem Therapeutics, Inc.
Cleared by FDA to proceed with the treatment in U.S. under Coronavirus Treatment Acceleration Program (CTAP)Pluristem’s main focus: multinational clinical trial of PLX cells for treatment of...
Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure
April 07, 2020 07:50 ET
|
Pluristem Therapeutics, Inc.
All treated patients were in Intensive Care Units (ICU) on ventilators and suffered from Acute Respiratory Distress Syndrome (ARDS)100% survival rate for all seven patients6 patients completed 1 week...
Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use
March 30, 2020 07:30 ET
|
Pluristem Therapeutics, Inc.
Expects to treat more patients in Israel in the coming daysCompany is in discussions with regulators in the U.S. and Europe to define its clinical strategy for COVID-19 HAIFA, Israel, March 30, 2020...
Pluristem Provides Update on COVID-19: Preparedness, Current Phase III Clinical Trials Status and Treatment Development Activity
March 26, 2020 08:00 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, March 26, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Israeli Ministry of Health Clears a Path to Allow Per Patient Compassionate Use Treatment of Covid-19 Patients with Pluristem’s PLX Cells
March 17, 2020 08:30 ET
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, March 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...